Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced Tuesday that debentureholders have converted $1.4 million of their principal into common shares at a price of $0.32 per share, resulting in the issuance of 4,375,000 common shares. The conversion represents 35% of the company's previously outstanding debenture principal of $4 million, significantly strengthening its balance sheet as it advances toward key milestones in its ongoing patient study program.
The conversion of debt into equity is expected to improve the company's financial flexibility and reduce ongoing interest costs while aligning investor interests with the continued advancement of Ocumetics' technology platform and clinical development objectives. The company continues to advance toward key regulatory milestones, including preparation for its planned Investigational Device Exemption (IDE) submission to the U.S. Food and Drug Administration.
"These debenture conversions reflect the confidence our investors and debenture holders continue to show in Ocumetics and our long-term vision," said Dean Burns, President and CEO of Ocumetics. "We are actively managing our investments and stakeholder relationships as we continue to advance our patient study and focus on achieving the next major milestones for the Company."
Ocumetics is a Canadian research and product development company dedicated to developing advanced vision correction solutions. The company is in the first-in-human early feasibility study phase of a dynamic intraocular lens that fits within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses. The lens is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses and without perceptible time lag.
By converting $1.4 million in debenture principal into equity, Ocumetics reduces its debt burden and interest obligations, freeing up capital for research and development activities. This financial restructuring comes at a critical time as the company prepares for its IDE submission to the FDA, a key step toward regulatory approval and commercialization. The move also signals strong investor confidence in Ocumetics' technology and its potential to transform the ophthalmic industry.
For more information on Ocumetics and its technology, visit the company's website or view the original release on NewMediaWire.
